Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Virpax Pharmaceuticals, Inc.

< Previous 1 2 Next >
Virpax Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals To Present at Upcoming CB Tech Watch Seminar
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference May 10-11, 2023
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Engages Dr. Pardeep Gupta to Assist in Development of Company’s Lead Asset, Probudur™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Reports 2022 Year-End Results
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Engages Destum Partners to Direct Strategic Global Partnering Efforts
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol™ (formerly VRP324)
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol™ (formerly VRP324)
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Reports 2022 Third Quarter Results
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Dr. Jeffrey Gudin, Chief Medical Officer of Virpax Pharmaceuticals, to Present Poster at World Congress of World Institute of Pain
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Reports 2022 Second Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Enters Into CRADA With The U.S. Army Institute of Surgical Research
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Successfully Completes Initial Preclinical Studies for VRP324
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Reports 2021 Year-End Results
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Expands AnQlar™ Development and Commercialization Rights Through Worldwide Licensing Agreement
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
News Outlets Highlight Virpax Pharmaceuticals and Its Potential Solutions for the Opioid Crisis and COVID-19
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Reports Favorable Preclinical Safety Data for Envelta™  for the Treatment of Acute and Chronic Pain
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax® Successfully Completes Preclinical Dermal Safety Studies for Epoladerm™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Reports 2021 Third Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Advances Envelta™ Development with NCATS Under CRADA Agreement
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax to Present at the NobleCon Online Pain Management Investor Forum on Channelchek.com on October 7, 2021
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax to Develop Intranasal Cannabidiol Product for the Management of Epilepsy in Adults and Children
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Reports 2021 Second Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Reports 2021 First Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.